


This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Currently Amended) Monoalkylaminoketone compounds of the formula I




in which

- R<sup>1</sup> denotes a saturated, unsaturated or aromatic carbocyclic or heterocyclic radical which is unsubstituted or mono- or polysubstituted by R<sup>3</sup> and/or R<sup>4</sup>,  
R<sup>2</sup> denotes alkyl having 1-20 C atoms,  
R<sup>3</sup>, R<sup>4</sup> each, independently of one another, denote H, alkyl or alkoxy having 1-20 C atoms, aryl, aryloxy or COOR<sup>2</sup>, F, Cl, Br, OH, CN, NO<sub>2</sub>, N(R<sup>2</sup>)<sub>2</sub> or NHCOR<sup>2</sup>,

and salts and solvates thereof.

2. (Currently Amended) (withdrawn) Process for the preparation of monoalkylaminoketone compounds of the formula I




in which

- R<sup>1</sup> denotes a saturated, unsaturated or aromatic carbocyclic or heterocyclic radical which is unsubstituted or mono- or polysubstituted by R<sup>3</sup> and/or R<sup>4</sup>,  
R<sup>2</sup> denotes alkyl having 1-20 C atoms,

$R^3, R^4$  each, independently of one another, denote H, alkyl or alkoxy having 1-20 C atoms, aryl, aryloxy or  $\text{COOR}^2$ , F, Cl, Br, OH, CN,  $\text{NO}_2$ ,  $\text{N(R}^2)_2$  or  $\text{NHCOR}^2$ ,

by reaction of compounds of the formula II




in which

$R^1$  and  $R^2$  have the meaning indicated above, in the presence of an alkylamine of the formula  $\text{R}^2\text{NH}_2$ , in which  $R^2$  has the meaning indicated above.

3. **(Previously presented) (withdrawn)**      Process according to Claim 2, in which  $R^1$  denotes phenyl or 2-thienyl.
4. **(Previously presented) (withdrawn)**      Process according to Claim 2, in which  $R^2$  denotes methyl, ethyl, n-propyl or isopropyl.
5. **(Previously presented) (withdrawn)**      Process for the preparation of compounds of the formula I according to claim 1, wherein the pH for the conversion of the compounds of the formula II into the compounds of the formula I is adjusted to about pH 2-7.5 by addition of an alkylamine of the formula  $\text{R}^2\text{NH}_2$ .
6. **(Previously presented) (withdrawn)**      Process for the preparation of compounds of the formula I according to claim 1, wherein the conversion of the compounds of the formula II into the compounds of the formula I is carried out at  $0^\circ - 200^\circ\text{C}$ .


7. **(Previously presented) (withdrawn)** Process for the preparation of compounds of the formula I according to claim 1, wherein firstly the compound of the formula II is obtained by reaction of a mixture of a formaldehyde source with a corresponding alkylammonium salt and a ketone of the formula III




in which R<sup>1</sup> has the meaning indicated in Claim 1,  
in the presence of a strong acid, and the compounds of the formula II obtained in this way are employed without further isolation for the preparation of the compounds of the formula I.

8. **(Previously presented) (withdrawn)** Process for the preparation of compounds of the formula I according to Claim 6, wherein the pH of the strongly acidic reaction mixture comprising the compounds of the formula II is increased to about pH 2-7.5, without further isolation of this compound, by addition of an alkylamine of the formula R<sup>2</sup>NH<sub>2</sub>, and the mixture is subsequently warmed.
9. **(Previously presented) (withdrawn)** Process for the preparation of compounds of the formula I according to Claim 7, wherein the reaction mixture comprising the compounds of the formula II is warmed to 0°C to 200°C after addition of a corresponding alkylamine.
10. **(Previously presented) (withdrawn)** Process according to claim 2 for the preparation of 3-methylamino-1-phenyl-1-propanone or 3-methylamino-1-(2-thienyl)-1-propanone.
11. **(Previously presented) (withdrawn)** Process according to claim 1, wherein an acid-addition salt of the compound of the formula II is employed, and an acid-addition salt of the compound of the formula I is obtained.

12. **(Previously presented)** A compound of claim 1 which is of the formula Ia:



13. (Previously presented) A compound of claim 1 which is of the formula 1b:



and salts and solvates thereof.

14. (Canceled)

15. (Previously presented) A compound of claim 1, wherein  $R^1$  denotes phenyl or 2-thienyl.

16. (Previously presented) A compound of claim 1, wherein  $R^2$  denotes methyl, ethyl, n-propyl or isopropyl.

17. (Previously presented) A compound of claim 1, wherein  $R^1$  is selected from: 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl,

2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo[1,4]oxazinyl, 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, 2,1,3-benzoxadiazol-5-yl, 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-dihydro-2H-benzo[1,4]oxazinyl, 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl, 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl, 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxofuranyl, each optionally substituted by R<sup>3</sup> and/or R<sup>4</sup>.